Hemophilia A is an X-linked bleeding disorder caused by a deficiency of factor VIII. Depending on the factor VIII activity in patient's plasma, we can have three different forms of hemophilia A: mild (5-40 IU/dl), moderate (1-5 IU/dl) and severe (<1 IU/dl). The most common symptoms include recurrent bleeding episodes of soft tissues and joints. The treatment is based on the prophylactic use of clotting factor concentrates to prevent bleeding episodes. We describe three cases of patients with initially diagnosis of hemophilia A that show different clinical severity, undergoing prophylactic therapies with low benefit. In these patients, the dosage of von Willebrand antigen revealed either low level or absence of this factor, which in one case was caused by the occurrence of a type III form of von Willebrand disease

Basso, M., Lazzareschi, I., Curatola, A., Di Gennaro, L., Buonsenso, D., Gatto, A., De Candia, E., De Cristofaro, R., Hemophilia A and von Willebrand deficiency: therapeutic implications, <<BLOOD COAGULATION & FIBRINOLYSIS>>, 2020; (N/A): N/A-N/A. [doi:10.1097/MBC.0000000000000908] [http://hdl.handle.net/10807/152624]

Hemophilia A and von Willebrand deficiency: therapeutic implications

Basso;Maria; Lazzareschi;Ilaria; Curatola;Antonietta; Di Gennaro;Leonardo; Buonsenso;Antonio; De Candia;Erica; De Cristofaro
2020

Abstract

Hemophilia A is an X-linked bleeding disorder caused by a deficiency of factor VIII. Depending on the factor VIII activity in patient's plasma, we can have three different forms of hemophilia A: mild (5-40 IU/dl), moderate (1-5 IU/dl) and severe (<1 IU/dl). The most common symptoms include recurrent bleeding episodes of soft tissues and joints. The treatment is based on the prophylactic use of clotting factor concentrates to prevent bleeding episodes. We describe three cases of patients with initially diagnosis of hemophilia A that show different clinical severity, undergoing prophylactic therapies with low benefit. In these patients, the dosage of von Willebrand antigen revealed either low level or absence of this factor, which in one case was caused by the occurrence of a type III form of von Willebrand disease
Inglese
Basso, M., Lazzareschi, I., Curatola, A., Di Gennaro, L., Buonsenso, D., Gatto, A., De Candia, E., De Cristofaro, R., Hemophilia A and von Willebrand deficiency: therapeutic implications, <<BLOOD COAGULATION & FIBRINOLYSIS>>, 2020; (N/A): N/A-N/A. [doi:10.1097/MBC.0000000000000908] [http://hdl.handle.net/10807/152624]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/152624
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact